Impaired facial emotion recognition in a ketamine model of psychosis

Psychiatry Research

Volumn 200, Issue 2-3, 2012, Pages 724-727

  Ebert, Andreas ^a   Haussleiter, Ida Sibylle ^a   Juckel, Georg ^a   Brüne, Martin ^a   Roser, Patrik ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Emotion recognition; Glutamate; Schizophrenia

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ARTICLE; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; EKMAN 60 FACES TEST; EMOTIONALITY; FACIAL EXPRESSION; HUMAN; HUMAN EXPERIMENT; LONELINESS; MALE; NEGATIVE SYNDROME; NORMAL HUMAN; PATTERN RECOGNITION; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; PSYCHOTOMIMETIC STATES INVENTORY; SELECTIVE ATTENTION; TASK PERFORMANCE;

ADULT; ATTENTION; EMOTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FACIAL EXPRESSION; HUMANS; KETAMINE; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; RECOGNITION (PSYCHOLOGY);

EID: 84872387821     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.06.034     Document Type: Article

References (35)

1. Abel K.M., Allin M.P., Kucharska-Pietura K., David A., Andrew C., Williams S., Brammer M.J., Phillips M.L. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 2003, 14:387-391.
2. Abramowicz A., Klatzky R.L., Lederman S.J. Learning and generalization in haptic classification of 2-draised-line drawings of facial expressions of emotion by sighted and adventitiously blind observers. Perception 1991, 39:1261-1275.
3. Alves-Neto W.C., Guapon V.G., Graeff F.G., Deakin J.F., Del-Ben C.M. Effect of escitalopram on the processing of emotional faces. Brazilian Journal of Medical and Biological Research 2010, 43:285-289.
4. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Schlögelhofer M., Mossaheb N., Werneck-Rohrer S., Nelson B., McGorry P.D. Emotion recognition in individuals at clinical high-risk for schizophrenia. Schizophrenia Bulletin 2011, 10.1093/schbul/sbr015.
5. Bedi G., Hyman D., de Wit H. Is ecstasy an "empathogen"? Effects of 3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biological Psychiatry 2010, 68:1134-1140.
6. Bediou B., Asri F., Brunelin J., Krolak-Salmon P., D'Amato T., Saoud M., Tazi I. Emotion recognition and genetic vulnerability to schizophrenia. British Journal of Psychiatry 2007, 191:126-130.
7. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47:351-354.
8. Brüne M. Emotion recognition, 'theory of mind' and social behavior in schizophrenia. Psychiatry Research 2005, 133:135-147.
9. Brüne M., Schaub D., Juckel G., Langdon R. Social skills and behavioral problems in schizophrenia: the role of mental state attribution, neurocognition and clinical symptomatology. Psychiatry Research 2011, 190:9-17.
10. Dyck M., Winbeck M., Leiberg S., Chen Y., Mathiak K. Virtual faces as a tool to study emotion recognition deficits in schizophrenia. Psychiatry Research 2010, 179:247-252.
11. Ekman P., Sorenson E.R., Friesen W.V. Pan-cultural elements in facial displays of emotion. Science 1969, 164:86-88.
12. Gilles C., Luthringer R. Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs. Journal of Psychopharmacology 2007, 21:272-282.
13. Gordon J.A. Testing the glutamate hypothesis of schizophrenia. Nature Neuroscience 2010, 13:2-4.
14. Gur R.E., Kohler C.G., Ragland J.D., Siegel S.J., Lesko K., Bilker W.B., Gur R.C. Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophrenia Bulletin 2006, 32:279-287.
15. Halperin J.M., Greenblatt E., Sharma U., Schwartz S.T. Assessment of the Continuous Performance Test: reliability and validity in a nonreferred sample. Journal of Consulting and Clinical Psychology 1991, 3:603-608.
16. Hevers W., Hadley S.H., Lüddens H., Amin J. Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits. Journal of Neuroscience 2008, 28:5383-5393.
17. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Molecular Psychiatry 2002, 7:837-844.
18. Kohler C.G., Bilker W., Hagendoorn M., Gur R.E., Gur R.C. Emotion recognition deficit in schizophrenia: association with symptomatology and cognition. Biological Psychiatry 2000, 48:127-136.
19. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 1994, 51:199-214.
20. Kim Y.T., Kwon D.H., Chang Y. Impairments of facial emotion recognition and theory of mind in methamphetamine abusers. Psychiatry Research 2011, 186:80-84.
21. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003, 169:215-233.
22. Leung J.S., Lee T.M., Lee C.C. Facial emotion recognition in Chinese with schizophrenia at early and chronic stages of illness. Psychiatry Research 2011, 190:172-176.
23. Mason O.J., Morgan C.J., Stefanovic A., Curran H.V. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophrenia Research 2008, 103:138-142.
24. Mancuso F., Horan W.P., Kern R.S., Green M.F. Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. Schizophrenia Research 2011, 125:143-151.
25. Mathew S.J., Shah A., Lapidus K., Clark C., Jarun N., Ostermeyer B., Murrough J.W. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012, 26:189-204.
26. Micallef J., Tardieu S., Gentile S., Fakra E., Jouve E., Sambuc R., Blin O. Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects. Neurophysiologie Clinique 2003, 33:138-147.
27. Michalopoulou P.G., Surguladze S., Morley L.A., Giampietro V.P., Murray R.M., Shergill S.S. Facial fear processing and psychotic symptoms in schizophrenia: functional magnetic resonance imaging study. British Journal of Psychiatry 2008, 192:191-196.
28. Montag C., Schubert F., Heinz A., Gallinat J. Prefrontal cortex glutamate correlates with mental perspective-taking. PLoS One 2008, 3:e3890.
29. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., Craft S., Olney J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
30. Pratt J.A., Winchester C., Egerton A., Cochran S.M., Morris B.J. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. British Journal of Pharmacology 2008, 153:S465-S470.
31. Schneider F., Gur R.C., Koch K., Backes V., Amunts K., Shah N.J., Bilker W., Gur R.E., Habel U. Impairment in the specificity of emotion processing in schizophrenia. American Journal of Psychiatry 2006, 163:442-447.
32. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59:S22-S33.
33. Turetsky B.I., Kohler C.G., Indersmitten T., Bhati M.T., Charbonnier D., Gur R.C. Facial emotion recognition in schizophrenia: when and why does it go away?. Schizophrenia Research 2007, 94:253-263.
34. Valentine G.W., Mason G.F., Gomez R., Fasula M., Watzl J., Pittman B., Krystal J.H., Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Research 2011, 191:122-127.
35. Young A., Perrett D., Calder A., Sprengelmeyer R., Ekman P. Ekman 60 Faces Test. Software Version 1.0 2002, Thames Valley Test Company, Thurston, Suffolk, UK.